54 related articles for article (PubMed ID: 32386450)
1. The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue.
Qadri S; Lallukka-Brück S; Luukkonen PK; Zhou Y; Gastaldelli A; Orho-Melander M; Sammalkorpi H; Juuti A; Penttilä AK; Perttilä J; Hakkarainen A; Lehtimäki TE; Orešič M; Hyötyläinen T; Hodson L; Olkkonen VM; Yki-Järvinen H
Liver Int; 2020 Sep; 40(9):2128-2138. PubMed ID: 32386450
[TBL] [Abstract][Full Text] [Related]
2. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
[TBL] [Abstract][Full Text] [Related]
3. PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein.
Johnson SM; Bao H; McMahon CE; Chen Y; Burr SD; Anderson AM; Madeyski-Bengtson K; Lindén D; Han X; Liu J
Nat Commun; 2024 Jun; 15(1):4847. PubMed ID: 38844467
[TBL] [Abstract][Full Text] [Related]
4. PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells.
Bruschi FV; Tardelli M; Einwallner E; Claudel T; Trauner M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218077
[TBL] [Abstract][Full Text] [Related]
5. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
bioRxiv; 2023 Oct; ():. PubMed ID: 37873239
[TBL] [Abstract][Full Text] [Related]
6. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
[TBL] [Abstract][Full Text] [Related]
7. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
Volkert I; Fromme M; Schneider C; Candels L; Lindhauer C; Su H; Thorhauge K; Pons M; Mohamed MR; Schneider KM; Strnad P; Trautwein C
Hepatology; 2024 Apr; 79(4):898-911. PubMed ID: 37625151
[TBL] [Abstract][Full Text] [Related]
8. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome.
Basantani MK; Sitnick MT; Cai L; Brenner DS; Gardner NP; Li JZ; Schoiswohl G; Yang K; Kumari M; Gross RW; Zechner R; Kershaw EE
J Lipid Res; 2011 Feb; 52(2):318-29. PubMed ID: 21068004
[TBL] [Abstract][Full Text] [Related]
9. The additive effects of the
Chen L; Du S; Lu L; Lin Z; Jin W; Hu D; Jiang X; Xin Y; Xuan S
Oncotarget; 2017 Sep; 8(43):74209-74216. PubMed ID: 29088779
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-ER-α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women.
Cherubini A; Casirati E; Pelusi S; Valenti L
Clin Transl Med; 2024 Jan; 14(1):e1524. PubMed ID: 38224202
[No Abstract] [Full Text] [Related]
11. Author Correction: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2024 Apr; 30(4):1212. PubMed ID: 38267549
[No Abstract] [Full Text] [Related]
12. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.
Luukkonen PK; Qadri S; Lehtimäki TE; Juuti A; Sammalkorpi H; Penttilä AK; Hakkarainen A; Orho-Melander M; Arola J; Yki-Järvinen H
J Clin Endocrinol Metab; 2021 Jan; 106(1):e300-e315. PubMed ID: 33064150
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity.
Lahelma M; Luukkonen PK; Qadri S; Ahlholm N; Lallukka-Brück S; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; Arola J; Orho-Melander M; Yki-Järvinen H
Nutrients; 2021 Jan; 13(1):. PubMed ID: 33429859
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
[TBL] [Abstract][Full Text] [Related]
16. MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
Luukkonen PK; Juuti A; Sammalkorpi H; Penttilä AK; Orešič M; Hyötyläinen T; Arola J; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2020 Sep; 73(3):725-726. PubMed ID: 32471727
[No Abstract] [Full Text] [Related]
17. Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis.
Seeßle J; Gan-Schreier H; Kirchner M; Stremmel W; Chamulitrat W; Merle U
BMC Gastroenterol; 2020 Jul; 20(1):230. PubMed ID: 32680469
[TBL] [Abstract][Full Text] [Related]
18. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth.
Monga Kravetz A; Testerman T; Galuppo B; Graf J; Pierpont B; Siebel S; Feinn R; Santoro N
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3575-85. PubMed ID: 32561908
[TBL] [Abstract][Full Text] [Related]
19. Shared genetic architecture and causal relationship between liver and heart disease.
Fang Z; Jia S; Mou X; Li Z; Hu T; Tu Y; Zhao J; Zhang T; Lin W; Lu Y; Feng C; Xia S
iScience; 2024 Apr; 27(4):109431. PubMed ID: 38523778
[TBL] [Abstract][Full Text] [Related]
20. Advances in genetic variation in metabolism-related fatty liver disease.
Shi F; Zhao M; Zheng S; Zheng L; Wang H
Front Genet; 2023; 14():1213916. PubMed ID: 37753315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
